MAP2K2 is altered in 0.92% of malignant solid tumor patients with MAP2K2 Mutation present in 0.68% of all malignant solid tumor patients [4].

MAP2K2 Mutation is an inclusion criterion in 17 clinical trials for malignant solid tumor, of which 15 are open and 2 are closed. Of the trials that contain MAP2K2 Mutation and malignant solid tumor as inclusion criteria, 9 are phase 1 (8 open), 2 are phase 1/phase 2 (2 open), and 6 are phase 2 (5 open) [5].

MAP2K2 is altered in 0.7% of non-small cell lung carcinoma patients with MAP2K2 Mutation present in 0.5% of all non-small cell lung carcinoma patients [4].

MAP2K2 Mutation is an inclusion criterion in 7 clinical trials for non-small cell lung carcinoma, of which 6 are open and 1 is closed. Of the trials that contain MAP2K2 Mutation and non-small cell lung carcinoma as inclusion criteria, 5 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [5].

MAP2K2 is altered in 2.76% of melanoma patients with MAP2K2 Mutation present in 2.54% of all melanoma patients [4].

MAP2K2 Mutation is an inclusion criterion in 4 clinical trials for melanoma, of which 4 are open and 0 are closed. Of the trials that contain MAP2K2 Mutation and melanoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [5].

MAP2K2 is altered in 0.91% of non-hodgkin lymphoma patients with MAP2K2 Mutation present in 0.38% of all non-hodgkin lymphoma patients [4].

MAP2K2 Mutation is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MAP2K2 Mutation and non-hodgkin lymphoma as inclusion criteria, 3 are phase 2 (2 open) [5].

MAP2K2 is altered in 1.13% of colorectal carcinoma patients with MAP2K2 Mutation present in 0.99% of all colorectal carcinoma patients [4].

MAP2K2 Mutation is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K2 Mutation and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 is altered in 0.77% of glioma patients with MAP2K2 Mutation present in 0.77% of all glioma patients [4].

MAP2K2 Mutation is an inclusion criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K2 Mutation and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

MAP2K2 is altered in 0.7% of low grade glioma patients with MAP2K2 Mutation present in 0.7% of all low grade glioma patients [4].

MAP2K2 Mutation is an inclusion criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K2 Mutation and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 is altered in 0.66% of thyroid gland carcinoma patients with MAP2K2 Mutation present in 0.44% of all thyroid gland carcinoma patients [4].

MAP2K2 Mutation is an inclusion criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K2 Mutation and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

MAP2K2 is altered in 1.32% of ovarian carcinoma patients with MAP2K2 Mutation present in 0.38% of all ovarian carcinoma patients [4].

MAP2K2 Mutation is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K2 Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 Mutation is an inclusion criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain MAP2K2 Mutation and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [5].

MAP2K2 is altered in 3.26% of cutaneous melanoma patients with MAP2K2 Mutation present in 2.88% of all cutaneous melanoma patients [4].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MAP2K2 is altered in 2.08% of pilocytic astrocytoma patients with MAP2K2 Mutation present in 2.08% of all pilocytic astrocytoma patients [4].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 is altered in 1.97% of endometrial carcinoma patients with MAP2K2 Mutation present in 1.71% of all endometrial carcinoma patients [4].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 is altered in 1.18% of esophageal carcinoma patients with MAP2K2 Mutation present in 1.03% of all esophageal carcinoma patients [4].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MAP2K2 is altered in 0.99% of astrocytic tumor patients with MAP2K2 Mutation present in 0.99% of all astrocytic tumor patients [4].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 is altered in 0.88% of diffuse glioma patients with MAP2K2 Mutation present in 0.88% of all diffuse glioma patients [4].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 is altered in 0.85% of squamous cell lung carcinoma patients with MAP2K2 Mutation present in 0.71% of all squamous cell lung carcinoma patients [4].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 is altered in 0.8% of breast carcinoma patients with MAP2K2 Mutation present in 0.45% of all breast carcinoma patients [4].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 is altered in 0.59% of gastric carcinoma patients with MAP2K2 Mutation present in 0.44% of all gastric carcinoma patients [4].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MAP2K2 is altered in 0.46% of cholangiocarcinoma patients with MAP2K2 Mutation present in 0.35% of all cholangiocarcinoma patients [4].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MAP2K2 is altered in 0.43% of pancreatic carcinoma patients with MAP2K2 Mutation present in 0.35% of all pancreatic carcinoma patients [4].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 is altered in 0.52% of soft tissue sarcoma patients with MAP2K2 Mutation present in 0.35% of all soft tissue sarcoma patients [4].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 is altered in 0.4% of pancreatic adenocarcinoma patients with MAP2K2 Mutation present in 0.32% of all pancreatic adenocarcinoma patients [4].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

MAP2K2 is altered in 0.37% of renal cell carcinoma patients with MAP2K2 Mutation present in 0.27% of all renal cell carcinoma patients [4].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 is altered in 0.1% of acute myeloid leukemia patients [4].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [5].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 is altered in 0.67% of poorly differentiated thyroid gland carcinoma patients [4].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for poorly differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

MAP2K2 Mutation is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 Mutation and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].